Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Early Phase 1
4(100.0%)
4Total
Early Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06532630Early Phase 1Recruiting

Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies

Role: lead

NCT06756321Early Phase 1Recruiting

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

Role: collaborator

NCT06586658Early Phase 1Recruiting

Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells

Role: collaborator

NCT06532643Early Phase 1Recruiting

Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma

Role: lead

All 4 trials loaded